Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands

Journal of Medicinal Chemistry

Volumn 56, Issue 8, 2013, Pages 3217-3227

  Hewings, David S ^a,b   Fedorov, Oleg ^b   Filippakopoulos, Panagis ^b   Martin, Sarah ^b   Picaud, Sarah ^b   Tumber, Anthony ^b   Wells, Christopher ^b   Olcina, Monica M ^a   Freeman, Katherine ^a   Gill, Andrew ^c   Ritchie, Alison J ^c   Sheppard, David W ^c   Russell, Angela J ^a   Hammond, Ester M ^a   Knapp, Stefan ^b   Brennan, Paul E ^b   Conway, Stuart J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BioFocus DPI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)[3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 ETHOXYPHENYL]METHANOL; (4 CHLOROPHENYL)[3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 ETHOXYPHENYL]METHANOL; 2 [3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 [HYDROXY(PHENYL)METHYL]PHENOXY]ETHANOL; 3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 [HYDROXY(PHENYL)METHYL]ACETATE; 3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 [HYDROXY(PHENYL)METHYL]PHENOL; 3,5 DIMETHYLISOXAZOLE DERIVATIVE; [3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 (2 METHOXYETHOXY)PHENYL](PHENYL)METHANOL; [3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 ETHOXYPHENYL](3 FLUOROPHENYL)METHANOL; [3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 ETHOXYPHENYL](4 FLUOROPHENYL)METHANOL; [3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 ETHOXYPHENYL](PHENYL)METHANOL; [3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 HYDROXYPHENYL]PHENYL]METHANOL; [3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 HYDROXYPHENYL]PHENYL]METHANONE; ACETIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; ISOXAZOLE DERIVATIVE; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; LEUKEMIA CELL; MOLECULAR WEIGHT; PROTEIN DOMAIN; STOICHIOMETRY; X RAY CRYSTALLOGRAPHY;

ACETYLATION; CELL LINE, TUMOR; CREB-BINDING PROTEIN; CRYSTALLOGRAPHY, X-RAY; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; ISOXAZOLES; LIGANDS; LYSINE; NUCLEAR PROTEINS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 84876833549     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301588r     Document Type: Article

References (38)

1. Allfrey, V.; Faulkner, R.; Mirsky, A. Acetylation and methylation of histones and their possible role in regulation of RNA synthesis Proc. Natl. Acad. Sci. U.S.A. 1964, 51, 786-794
2. Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 2000, 19, 1176-1179
3. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 2012, 11, 384-400
4. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications Nature 2000, 403, 41-45
5. Gardner, K. E.; Allis, C. D.; Strahl, B. D. Operating on chromatin, a colorful language where context matters J. Mol. Biol. 2011, 409, 36-46
6. Conway, S. J. Bromodomains: Are readers right for epigenetic therapy? ACS Med. Chem. Lett. 2012, 3, 691-694
7. Dhanak, D. Cracking the code: the promise of epigenetics ACS Med. Chem. Lett. 2012, 3, 521-523
8. Zeng, L.; Zhou, M. Bromodomain: an acetyl-lysine binding domain FEBS Lett. 2002, 513, 124-128
9. Filippakopoulos, P.; Knapp, S. The bromodomain interaction module FEBS Lett. 2012, 586, 2692-2704
10. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.-P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A.-C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231
11. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 2011, 13, e29
12. Prinjha, R. K.; Witherington, J.; Lee, K. Place your BETs: the therapeutic potential of bromodomains Trends Pharmacol. Sci. 2012, 33, 146-153
13. Chung, C.-W.; Tough, D. F. Bromodomains: a new target class for small molecule drug discovery Drug Discovery Today: Ther. Strategies 2012, 9, e111-e120
14. Chung, C.-W. Small molecule bromodomain inhibitors: extending the druggable genome Prog. Med. Chem. 2012, 51, 1-55
15. Brennan, P.; Filippakopoulos, P.; Knapp, S. The therapeutic potential of acetyl-lysine and methyl-lysine effector domains Drug Discovery Today: Ther. Strategies 2012, 9, e101-e110
16. Hewings, D. S.; Rooney, T. P. C.; Jennings, L. E.; Hay, D. A.; Schofield, C. J.; Brennan, P. E.; Knapp, S.; Conway, S. J. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions J. Med. Chem. 2012, 55, 9393-9413
17. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
18. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123
19. Adachi, K.; Hikawa, H.; Hamada, M.; Endoch, J.-I.; Ishibichi, S.; Fujie, N.; Tanaka, M.; Sugahara, K.; Oshita, K.; Murata, M. Thienotriazolodiazepine Compound and a Medicinal Use Thereof. PCT/JP2006/310709 (WO/2006/129623), 2006.
20. Miyoshi, S.; Ooike, S.; Iwata, K.; Hikawa, H.; Sugahara, K. Antitumor Agent. PCT/JP2008/073864 (WO/2009/084693), 2009.
21. Chung, C.-W.; Coste, H.; White, J. H.; Mirguet, O.; Wilde, J.; Gosmini, R. L.; Delves, C.; Magny, S. M.; Woodward, R.; Hughes, S. A.; Boursier, E. V.; Flynn, H.; Bouillot, A. M.; Bamborough, P.; Brusq, J.-M. G.; Gellibert, F. J.; Jones, E. J.; Riou, A. M.; Homes, P.; Martin, S. L.; Uings, I. J.; Toum, J.; Clément, C. A.; Boullay, A.-B.; Grimley, R. L.; Blandel, F. M.; Prinjha, R. K.; Lee, K.; Kirilovsky, J.; Nicodeme, E. Discovery and characterization of small molecule inhibitors of the BET family bromodomains J. Med. Chem. 2011, 54, 3827-3838
22. Filippakopoulos, P.; Picaud, S.; Fedorov, O.; Keller, M.; Wrobel, M.; Morgenstern, O.; Bracher, F.; Knapp, S. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family Bioorg. Med. Chem. 2012, 20, 1878-1886
23. Zhang, G.; Liu, R.; Zhong, Y.; Plotnikov, A. N.; Zhang, W.; Zeng, L.; Rusinova, E.; Gerona-Nevarro, G.; Moshkina, N.; Joshua, J.; Chuang, P. Y.; Ohlmeyer, M.; He, J. C.; Zhou, M.-M. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition J. Biol. Chem. 2012, 287, 28840-28851
24. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands J. Med. Chem. 2011, 54, 6761-6770
25. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W.-I.; Robson, S. C.; Chung, C.-W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J. P.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533
26. Hay, D.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Philpott, M.; Picaud, S.; Hewings, D. S.; Uttakar, S.; Heightman, T. D.; Conway, S. J.; Knapp, S.; Brennan, P. E. The design and synthesis of 5 and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains Med. Chem. Commun. 2013, 4, 140-144
27. Fish, P. V.; Filippakopoulos, P.; Bish, G.; Brennan, P. E.; Bunnage, M. E.; Cook, A. S.; Federov, O.; Gerstenberger, B. S.; Jones, H.; Knapp, S.; Marsden, B.; Nocka, K.; Owen, D. R.; Philpott, M.; Picaud, S.; Primiano, M. J.; Ralph, M. J.; Sciammetta, N.; Trzupek, J. D. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit J. Med. Chem. 2012, 55, 9831-9837
28. Chung, C.-W.; Dean, A. W.; Woolven, J. M.; Bamborough, P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery J. Med. Chem. 2012, 55, 576-586
29. Bamborough, P.; Diallo, H.; Goodacre, J. D.; Gordon, L.; Lewis, A.; Seal, J. T.; Wilson, D. M.; Woodrow, M. D.; Chung, C.-W. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides J. Med. Chem. 2012, 55, 587-596
30. Philpott, M.; Yang, J.; Tumber, T.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Keates, T.; Felletar, I.; Ciulli, A.; Knapp, S.; Heightman, T. D. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery Mol. BioSyst. 2011, 7, 2899-2908
31. Dunitz, J. D. The entropic cost of bound water in crystals and biomolecules Science 1994, 264, 670
32. Ellermann, M.; Jakob-Roetne, R.; Lerner, C.; Borroni, E.; Schlatter, D.; Roth, D.; Ehler, A.; Rudolph, M. G.; Diederich, F. Molecular recognition at the active site of catechol- o -methyltransferase: energetically favorable replacement of a water molecule imported by a bisubstrate inhibitor Angew. Chem., Int. Ed. 2009, 48, 9092-9096
33. Kohler, P. C.; Ritschel, T.; Schweizer, W. B.; Klebe, G.; Diederich, F. High-affinity inhibitors of tRNA-guanine transglycosylase replacing the function of a structural water cluster Chem.-Eur. J. 2009, 15, 10809-10817
34. Salonen, L. M.; Holland, M. C.; Kaib, P. S. J.; Haap, W.; Benz, J.; Mary, J.-L.; Kuster, O.; Schweizer, W. B.; Banner, D. W.; Diederich, F. Molecular recognition at the active site of factor Xa: cation-π interactions, stacking on planar peptide surfaces, and replacement of structural water Chem.-Eur. J. 2012, 18, 213-222
35. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528
36. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J. Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 16669-16674
37. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917
38. Srivastava, V.; Tandon, A.; Ray, S. Convenient and selective acetylations of phenols, amines and alcohols Synth. Commun. 1992, 22, 2703-2710